Best practice & research. Clinical endocrinology & metabolism最新文献_第3页

Traumatic brain injury and hypopituitarism 外伤性脑损伤和垂体功能减退。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-05-01 DOI: 10.1016/j.beem.2025.102021

Professor Fahrettin Kelestimur

引用次数: 0

Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury 外伤性脑损伤患者神经内分泌异常的病理生理学及诊断

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-05-01 DOI: 10.1016/j.beem.2025.102020

Ulla Feldt-Rasmussen , Marianne Christina Klose

引用次数: 0

Neuroendocrine dysfunction following traumatic brain injury: Current insights and emerging perspectives 创伤性脑损伤后的神经内分泌功能障碍：当前的见解和新兴的观点。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-05-01 DOI: 10.1016/j.beem.2025.102006

Shumaila Hasan , Chris Uff

引用次数: 0

Epidemiology and risk factors for hypopituitarism due to traumatic brain injury 外伤性脑损伤所致垂体功能减退的流行病学及危险因素。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-05-01 DOI: 10.1016/j.beem.2025.101997

Kursad Unluhizarci, Emre Urhan

引用次数: 0

Localization in primary hyperparathyroidism 原发性甲状旁腺功能亢进的定位。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2024.101967

Piyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, Bhagwant Rai Mittal

{"title":"Localization in primary hyperparathyroidism","authors":"Piyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, Bhagwant Rai Mittal","doi":"10.1016/j.beem.2024.101967","DOIUrl":"10.1016/j.beem.2024.101967","url":null,"abstract":"<div><div>Primary hyperparathyroidism is the main cause of hypercalcemia, resulting predominantly from parathyroid adenomas followed by hyperplasia. Diagnosis relies on clinical and biochemical parameters. Accurate pre-operative localization is mandatory for better surgical outcome. Various non-invasive imaging modalities includes cervical ultrasound, radionuclide scintigraphy with <sup>99m</sup>Tc-Methoxyisobutyl isonitrile combined with SPECT/CT, 4DCT, MRI and <sup>18</sup>F-Choline PET/CT. Functional imaging has shown higher accuracy in localization especially in ectopic parathyroid adenomas and persistent or recurrent hyperparathyroidism. Combined ultrasound and <sup>99m</sup>Tc-MIBI has shown high sensitivity and specificity than individual imaging modality. <sup>18</sup>F-Choline PET/CT has better diagnostic performance in identifying parathyroid hyperplasia and multiple adenomas. In patients with equivocal findings and concurrent thyroid nodular diseases, <sup>18</sup>F-Choline PET/MRI and 4DCT helps in better characterization of lesion. Intraoperative probe guided surgery facilitates targeted and minimally invasive surgery resulting in better surgical outcome. More specific radiopharmaceuticals for parathyroid imaging need to be developed to reduce false positive results.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 2","pages":"Article 101967"},"PeriodicalIF":6.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heritable hyperparathyroidism: Genetic insights and clinical implications 遗传性甲状旁腺功能亢进症：遗传学见解和临床意义。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2025.101984

Ashna Grover , Smita Jha

引用次数: 0

Parathyroid carcinoma: New insights 甲状旁腺癌：新见解。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2024.101966

Abhishek Viswanath , Eftychia E. Drakou , Fannie Lajeunesse-Trempe , Ashley B. Grossman , Georgios K. Dimitriadis

{"title":"Parathyroid carcinoma: New insights","authors":"Abhishek Viswanath , Eftychia E. Drakou , Fannie Lajeunesse-Trempe , Ashley B. Grossman , Georgios K. Dimitriadis","doi":"10.1016/j.beem.2024.101966","DOIUrl":"10.1016/j.beem.2024.101966","url":null,"abstract":"<div><div>Parathyroid carcinoma (PC) is a rare malignancy, comprising 1 % of all cases of primary hyperparathyroidism (PHPT). This narrative review explores recent advances in PC management, with a focus on molecular insights, diagnostic advancements, surgical innovations, and emerging targeted therapies. Manuscripts published between 2023 and 2024 were obtained from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The review highlights advances in biochemical markers, such as circulating tumour cells (CTCs), and imaging modalities such as <sup>18</sup>F-FDG PET/CT and 4D-CT, which are improving diagnostic accuracy. Surgical resection remains central to localised and metastatic disease management. For patients with widespread metastatic or unresectable disease, newer targeted approaches such as tyrosine kinase inhibitors (TKIs), temozolomide, and immune checkpoint inhibitors (ICIs) may offer clinical benefit to specific patient cohorts. This review identifies future research areas to improve outcomes and recommends that patients with advanced PC continue to be managed in centres of excellence.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 2","pages":"Article 101966"},"PeriodicalIF":6.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis 散发性原发性甲状旁腺功能亢进的分子基础：发病机制的新前沿。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2025.101985

Ashutosh Kumar Arya , Poonam Kumari , Priyanka Singh , Sanjay Kumar Bhadada

{"title":"Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis","authors":"Ashutosh Kumar Arya , Poonam Kumari , Priyanka Singh , Sanjay Kumar Bhadada","doi":"10.1016/j.beem.2025.101985","DOIUrl":"10.1016/j.beem.2025.101985","url":null,"abstract":"<div><div>Primary hyperparathyroidism is a common endocrine disorder characterized by inappropriate elevation of parathyroid hormone and hypercalcemia. While predominantly an asymptomatic disease in Western populations, symptomatic presentations are more prevalent in Eastern countries. The molecular pathogenesis of sporadic PHPT primarily involves genetic and epigenetic alterations leading to abnormal parathyroid cell proliferation and altered calcium sensing mechanism. To date, MEN1 and cyclin D1 are the only established drivers of sporadic PHPT. Somatic MEN1 gene mutations occur in 30–40 % of sporadic parathyroid adenomas (PA), with a recent study on symptomatic cases reporting germline variants.Cyclin D1 overexpression in sporadic PA has been observed in 20–40 % of cases in Western populations and 80 % of cases in Eastern populations, with an inverse association with cyclin-dependent kinase inhibitors CDKN2A and CDKN2B expression. The calcium-sensing receptor expression was significantly lower in symptomatic compared to asymptomatic PHPT, strongly supported by epigenetic deregulation (promoter hypermethylation and histone methylation). Recent studies have highlighted the potential involvement of EZH2, a histone methyltransferase, in parathyroid tumorigenesis. Additionally, parathyroid-specific transcription factors like GCM2, PAX1, and GATA3 are emerging as putative tumor suppressors, especially from the symptomatic PHPT. Next-generation sequencing has identified novel potential drivers such as PIK3CA, MTOR, and NF1 in sporadic PC, alongside CDC73. The molecular landscape of sporadic PHPT appears to differ between Eastern and Western populations. This heterogeneity underscores the need for further large-scale studies, particularly in symptomatic cases from developing nations, to comprehensively elucidate the molecular drivers of parathyroid tumorigenesis.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 2","pages":"Article 101985"},"PeriodicalIF":6.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing trends in clinical presentation of primary hyperparathyroidism across countries over time 随着时间的推移，各国原发性甲状旁腺功能亢进临床表现的变化趋势。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2025.101980

Durairaj Arjunan , Salvatore Minisola , Sudhaker D. Rao , Sanjay K. Bhadada

{"title":"Changing trends in clinical presentation of primary hyperparathyroidism across countries over time","authors":"Durairaj Arjunan , Salvatore Minisola , Sudhaker D. Rao , Sanjay K. Bhadada","doi":"10.1016/j.beem.2025.101980","DOIUrl":"10.1016/j.beem.2025.101980","url":null,"abstract":"<div><div>Primary hyperparathyroidism (PHPT), the third most common endocrine disorder, was so eloquently described first by Fuller Albright as a polymorphic condition in his classic paper and monograph as early as 1934. Over the decades, the clinical presentation of PHPT in developed countries has shifted significantly from a disease primarily affecting the bones and kidneys to an asymptomatic condition often discovered incidentally. In developing countries, the high prevalence of vitamin D deficiency is one of the main factors influencing the clinical presentation of PHPT. In Europe and North America, PHPT is predominantly asymptomatic. In South America, China, and Eastern parts of Europe, such as Turkey, Bulgaria, and Russia, there is an ongoing transition from symptomatic to asymptomatic cases. Asia shows variability: symptomatic cases dominate in the Indian subcontinent, Middle East, and Southeast Asia, while transitional patterns with predominant asymptomatic cases have now been reported in China, and Japan reports mostly asymptomatic cases. Factors influencing these changes include advancements in diagnostic technologies, detection of incidental parathyroid adenomas during thyroid ultrasonography, regional differences in vitamin D deficiency, dietary habits, and genetic polymorphisms in vitamin D and calcium-sensing receptors. A higher prevalence of nephrolithiasis in certain climates contributes to regional variations. This review examines the dynamic nature of PHPT's clinical presentation, shaped by geographic, genetic, and environmental influences. Also, this review highlights the importance of addressing global disparities in an attempt to optimize patient outcomes.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 2","pages":"Article 101980"},"PeriodicalIF":6.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congenital primary hyperparathyroidism 先天性原发性甲状旁腺功能亢进。

IF 6.1 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2025-03-01 DOI: 10.1016/j.beem.2025.101982

Francesca Marini , Francesca Giusti , Maria Luisa Brandi

引用次数: 0